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Background: The counselling of poor ovarian responders about the probability of pregnancy remains a puzzle for
gynaecologists. The aim of this study was to optimise the management of poor responders by investigating the
role of the oocyte-derived factor bone morphogenetic protein-15 (BMP-15) combined with chronological age in
the prediction of the outcome of in-vitro fertilisation-embryo transfer (IVF-ET) in poor responders.
Methods: A retrospective study conducted in a university hospital. A total of 207 poor ovarian responders who
reached the ovum pick-up stage undergoing IVF/intracytoplasmic sperm injection (ICSI) with three or fewer follicles
no less than 14 mm on the day of oocyte retrieval were recruited from July 1, 2008 to December 31, 2009. Another
215 coinstantaneous cycles with normal responses were selected as controls. The BMP-15 levels in the follicular
fluid (FF) of the 207 poor responders were analysed by western blot. Based on the FF BMP-15 level and age, poor
responders were sub-divided into four groups. The main outcome measures were the FF BMP-15 level, implantation
rate, pregnancy rate, and live birth rate.
Results: The implantation rate (24.2% vs. 15.3%), chemical pregnancy rate (40% vs. 23.7%), clinical pregnancy rate
(36.5% vs. 20.4%) and live birth rate (29.4% vs. 15.1%) in the high BMP-15 group were significantly higher than
those in the low BMP-15 group. Furthermore, poor responders aged less than or equal to 35 years with a higher FF
BMP-15 level had the best implantation, pregnancy and live birth rates, which were comparable with those of
normal responders.
Conclusions: Our study suggests a potential role of BMP-15 in the prediction of the IVF outcome. A high FF
BMP-15 combined with an age less than or equal to 35 years may be used as a potential indicator for repeating IVF
cycles in poor ovarian responders.
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Poor ovarian response is a major challenge in in-vitro
fertilisation-embryo transfer (IVF-ET). Because many
women today are postponing pregnancy and the average
age of IVF patients has increased correspondingly, poor
response is not a rare occurrence in ovarian stimulation
and has become part of the daily clinical management
for clinicians in IVF centres [1]. According to our clin-
ical experience, few poor responders would like to give
up an initiated cycle with most wanting to know the
chance of conception during the next cycle if they were
not pregnant. Appropriate counseling would help patients
decide whether to continue or stop IVF treatment to avoid
both unnecessary economic losses and health risks. Many
hormonal and ultrasound markers, such as age, basal
serum follicle stimulating hormone (FSH) level, serum
anti-Mullerian hormone levels and the number of antral
follicles, have been developed to predict the cycle success
or identify patients at high risk of poor response before
ovulation induction [2-4]. However, there is still no ideal
and consistent predictive marker of IVF outcome for poor
ovarian responders.
The oocyte has a central role in regulating follicle
growth and ovulation by producing oocyte-derived fac-
tors [5]. These oocyte-derived factors, such as growth
differentiation factor-9 (GDF-9) and bone morpho-
genetic protein-15 (BMP-15), may determine the sensi-
tivity of follicles to FSH and the selection of follicles to
the dominant follicles that continue growth to the pre-
ovulatory stage [6]. BMP-15, one of the most important
oocyte-derived factors, plays an essential role in female
fertility [5]. Variants of the BMP-15 gene have been
associated with premature ovarian failure and ovarian
hyperstimulation syndrome in women [7,8]. BMP-15 is a
key mitogenic factor for somatic cells and a stimulator
of granulosa cell proliferation [9]. Importantly, our pre-
vious study demonstrated a correlation of the BMP-15
level in follicular fluid (FF) with oocyte quality and sub-
sequent embryo development [10].
Female age has been well established to be the most
significant factor influencing clinical IVF outcome, asso-
ciated with reduced oocytes and increased early preg-
nancy loss. Herein, we hypothesized that the BMP-15
levels in FF combined with maternal age might be a can-
didate marker for the prediction of IVF outcomes in
poor responders. In the present study, we investigated
the relationship among FF BMP-15 level, maternal age
and outcome in poor ovarian responders.
Methods
Patients
The protocol was approved by the Institutional Review
Board of Zhejiang University School of Medicine.
Informed consents were obtained from all participants.Poor responders were defined as women having 3 or
fewer follicles with a diameter ≥ 14 mm on the day of
oocyte retrieval. Normal responders were defined as
those having 4 to 12 such follicles [11]. The exclusion
criteria were endometriosis, hyperprolactinemia and
polycystic ovarian syndrome. Women who are in their
40s have a significantly reduced chance of achieving
pregnancy and delivery by means of IVF compared with
women who are in their 30s. Thus we only included
women who were less than 40 years of age in this study.
A total of 207 infertile women undergoing IVF/ICSI
treatment were recruited from July 1, 2008 to December
31, 2009 at the Centre for Reproductive Medicine,
Women’s Hospital, Zhejiang University School of Medi-
cine, China. Moreover, 215 age-matched normal respon-
ders were recruited as controls.
Protocol and collection of follicular fluid
Pituitary desensitisation was commenced during the
luteal phase preceding IVF treatment with the gonado-
tropin releasing hormone agonist, triptorelin, at 0.1 mg
per day (Decapeptyl; Ferring, Malmo, Sweden). Follicle
growth was stimulated from day 3 of the menstrual cycle
by injecting recombinant FSH (Gonal-F; Serono,
Abonne, Switzerland) at 300IU/d for the first 2 days, fol-
lowed by the administration of rFSH at 150–225 IU/d
(for women with basal FSH<10 or aged ≤35 years) or
225–300 IU/d (for women with basal FSH>10 or aged
>35 years) with adjustment as necessary according to
the serum estradiol levels and transvaginal ultrasonog-
raphy. A total of 10000 IU of urinary human chorionic
gonadotrophin (uHCG, Livzon, China) was administered
when the leading follicle reached 18–22 mm in diameter,
as detected by ultrasound. Oocyte retrieval was performed
36 hours later under transvaginal ultrasound guidance.
Clean follicular fluid was collected by trans-vaginal
ultrasound-guided puncture and aspiration of 18–20
mm follicles. Only the fluid from the first aspirated fol-
licle of each patient was carefully collected to avoid
blood contamination. FF samples were centrifuged at
2647g for 10 min and stored at −70°C until the assay.
According to the cause of infertility, fertilisation was
conducted by IVF or ICSI, as determined by our clini-
cians independently. Fertilisation was considered normal
when the oocytes contained 2 pronuclei. The embryo
transfer was performed on day 2 or 3, depending on the
embryo quality and quantity. A pregnancy test was per-
formed at 2 weeks and an ultrasound examination at 4
weeks after the embryo transfer. Each pregnant woman
was followed up until pregnancy termination. The im-
plantation rate was defined as the percentage of embryos
transferred that implanted and developed to the stage of
ultrasound documented fetal heartbeat. Chemical preg-
nancy was defined as a positive result for pregnancy by a
Figure 1 Relative BMP-15 levels in poor responders. A: Western
blotting analysis of the BMP-15 protein in follicular fluid. The BMP-15
in 0.4 μl of FF following SDS gel electrophoresis, transfer and
blotting on a nitrocellulose membrane with a polyclonal antibody.
B: Comparison of the relative levels of BMP-15 in follicular fluid by
western blotting analysis in poor responders. The level of follicular
fluid BMP-15 in the high BMP-15 group was significantly higher than
that in the low BMP-15 group (**P < 0.001).
Table 1 Comparison of the characteristics and outcomes






BMP-15 level 0.95 (0.64–1.12) 1.35 (1.18–2.09) <0.001a
Age (yrs) 34 (24–39) 34 (25–39) 0.670a
BMI (kg/m2) 21.5 (15.8–33.8) 22.0 (15.2–28.0) 0.270 a
Basal FSH (IU/L) 7.46 (3.28–18.73) 8.0 (3.19–17.29) 0.137a
No. of oocytes retrieved 3 (0–7) 3 (0–7) 0.396a
ET cycle/started cycle 81.8% 84.5% 0.602b
No. of embryos transferred 2 (0–3) 2 (0–3) 0.477a







Live born rate/ET cycle 15.6% 30.5% 0.019b
Miscarriage rate 26.3% 19.4% 0.567b
a Values presented as medians (ranges) and compared by the Mann-Whitney-U test.
b Values are compared with Chi-square test (likelihood ratio).
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the presence of an intrauterine gestational sac on the
trans-vaginal ultrasound examination.
Analysis of BMP-15 level in FF
BMP-15 protein level in FF was analysed by Western
blotting as previously described [9,10]. Briefly, 400 nano-
liters of FF was diluted with 0.4 μl of lysis buffer (20 mM
Tris pH 7.4, 150 mM NaCl, 2 mM ethylenediaminete-
traacetic acid, 0.1% sodium dodecyl sulphate [SDS], 1%
Triton X-100, 0.5% sodium deoxycholate, 10% glycerol)
and electrophoresed on 12% SDS polyacrylamide gel
electrophoresis under reducing conditions. The separated
proteins were transferred onto nitrocellulose membranes,
which were then blocked for 1 h in Tris-buffered saline
(TBS) containing 5% non-fat dry milk. Subsequently, the
membranes were incubated with an antibody against
BMP-15 (1:5000, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) in TBS-Tween 20 and then incubated with
anti-rabbit IgG (1:40000, Santa Cruz Biotechnology) in
TBS-Tween 20. The membranes were washed several
times with TBS Tween 20 after each step and visualised
with an enhanced chemiluminescence system (Amersham
Pharmacia Biotech, Freiburg, Germany). The images were
scanned with the Bio-Rad GS800 densitometer (Bio-Rad
Laboratories, Hercules, CA, USA) and analyzed using
Quantity One software (Bio-Rad). The FFs of three ran-
dom poor responders were pooled to generate a standard
sample, which was included in each blot as a reference
to permit comparison between blots. The intensities of
individual bands were expressed as arbitrary absorbency
units and normalised to the standard sample. The mea-
surement was duplicated for each sample, and the values
were averaged before the statistical analysis.
Statistical analysis
The statistical analysis was performed with the Statistical
Package for the Social Sciences. Continuous variables
were presented as medians (ranges) and analysed using
the Kruskal-Wallis test or Mann–Whitney-U test. The
chi-square test and likelihood ratios were used to com-
pare IVF outcomes. For all analyses, the significance was
set at P < 0.05.
Results
A total of 207 poor responders and 207 normal respon-
ders were recruited in this study. These women were
aged 24–39 years, and their mean age was 34 years. Only
the first-puncture, clear FF samples from each patient
were analysed to avoid blood contamination. Overall,
207 FF samples from the poor responders were col-
lected. Western blotting analysis showed a single band
at approximately 45 kDa, which represented BMP-15,
in all 207 poor responder FF samples (Figure 1). Theaverage level of the BMP-15 protein was 1.17 (normal-
ised to the standard sample). Based on the FF BMP-15
levels of the 207 poor responders, they were divided into
a high BMP-15 group (higher than the mean value) and
a low BMP-15 group (lower than the mean value). As
shown in Table 1, age, body mass index (BMI), basal
FSH, number of retrieved oocytes, ET cycles and number
Table 3 Comparison of the characteristics and IVF
outcomes between poor responders aged ≤35 years with
high FF BMP-15 levels and normal responders
Parameter Poor responders






No. of oocytes retrieved 3 (0–7) 9 (3–21) <0.001a
ET cycle/started cycle 83.9% 95.8% 0.004b
No. of embryos transferred 2 (0–3) 2 (0–3) <0.001a







Live birth rate/ET cycle 38.3% 37.4% 0.907b
Miscarriage rate 5.3% 18.7% 0.121b
a Values presented as medians (ranges) and compared by the Mann-Whitney-U test.
b Values are compared with Chi-square test (likelihood ratio).
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between the two groups. However, the implantation rate
(25.3% vs. 15%), chemical pregnancy rate (41.5% vs.
23.3%), clinical pregnancy rate (37.8% vs. 21.1%) and live
birth rate (30.5% vs. 15.6%) were significantly higher in
the high BMP-15 group than in the low BMP-15 group
(Table 1, P<0.05).
According to a maternal age cut-off of 35 years, the
high BMP-15 and low BMP-15 groups were further
divided into four sub-groups, as shown in Table 2. The
number of retrieved oocytes, ET cycles and transferred
embryos were comparable among the sub-groups. The
low BMP-15 sub-group older than 35 years had the lowest
implantation (6.5%) and clinical pregnancy (12.5%) rates.
The high BMP-15 sub-group younger than 35 years had
the highest live birth rate (38.3%) among the four sub-
groups, which was significantly higher than that in the low
BMP-15 sub-group older than 35 years (Table 2). Notably,
poor responders older than 35 years with either high or
low BMP-15 levels had a significantly higher miscarriage
rate than high BMP-15 patients aged ≤35 years.
Table 3 demonstrates the cycle details and outcomes
of poor responders aged ≤ 35 with high FF BMP-15
levels, and those of normal responders. The number of
retrieved oocytes, ET cycles and number of transferred
embryos in the normal responders were significantly
higher than those in the poor responders. However, there
were no significant differences in the implantation rateTable 2 Comparison of the characteristics and IVF outcomes a
and age
Parameter Low BMP-15 (110)
Group 1 Group 2
(Age≤35, n=67) (35<Age<40, n
No. of oocytes retrieved 3 (0–7) 3 (0–7)
ET cycle/started cycle 86.6% 74.4%
No. of embryos transferred 2 (0–3) 2 (0–3)
Implantation rate/embryo 20.4% 6.5%
Chemical pregnancy rate/ET cycle 27.6% 15.6%
Clinical pregnancy rate/ET cycle 25.9% 12.5%
Live birth rate/ET cycle 20.7% 6.25%
Miscarriage rate 20% 50%
a Values presented as medians (ranges) and compared across four groups by the Kr
b Comparison across four groups (likelihood ratio).
c Group 1 vs. Group 2 (likelihood ratio).
d Group 2 vs. Group 3 (likelihood ratio).
e Group 2 vs. Group 4 (likelihood ratio).
f Group 3 vs. Group 4 (likelihood ratio).(28.9% vs. 24.8%), chemical pregnancy rate (44.7% vs.
47.1%), clinical pregnancy rate (40.4% vs. 45.6%) and live
birth rate (38.3% vs. 37.4%) between the two groups.
Discussion
The quality and quantity of the retrieved oocytes are the
major factors affecting IVF outcomes. For poor respon-
ders, numerous ovarian reserve tests have been developed
to predict the response to ovarian stimulation [1,2,11,12].mong poor responders subdivided by FF BMP-15 level
High BMP-15 (97) P value
Group 3 Group 4
=43) (Age≤35, n=56) (35<Age<40, n=41)
3 (0–7) 3 (0–6) 0.300a
83.9% 85.4% 0.415b










5.3% 41.7% 0.035d 0.012f
uskal-Wallis tests.
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assessing the quantity of follicles are widely performed.
However, few methods have been established to evaluate
the quality of the oocytes. In the present study, we found
a role for the oocyte-derived factor, BMP-15, in predicting
IVF outcome in poor responders, which may facilitate the
further management of these patients.
First, we divided the 207 poor responders into a high
BMP-15 group and a low BMP-15 group according to
their FF BMP-15 levels. Both groups were comparable in
terms of age, but the implantation and pregnancy rates
were significantly higher in the high BMP-15 group.
These data suggest that FF BMP-15 may be an effective
marker of oocyte quality and IVF performance indepen-
dent of age. This result is consistent with our previous
study, which showed that oocytes retrieved from follicles
with a high FF BMP-15 level had higher fertilisation rates
and a better quality of developed embryos [10].
The potential role of BMP-15 in oocyte development
competence and pregnancy outcome is well grounded. In
ovary, it is exclusively produced by oocytes [5]. BMP-15
has been shown to stimulate undifferentiated granulosa
cell proliferation, regulate granulosa cell differentiation
[9], and inhibit FSH action by suppressing the sensitivity
of granulosa cells to FSH stimulation [13]. Importantly,
BMP-15 is also involved in the selection of the dominant
follicle and in oocyte maturation by cooperating with FSH
[14]. Moreover, BMP-15 may contribute to the mainte-
nance of the low incidence of cumulus cell apoptosis by
establishing a localized gradient [15], and it induces cumu-
lus cell expansion by enhancing the expression of epider-
mal growth factor-like growth factor [16]. Interestingly,
BMP-15 can promote glycolysis in cumulus cells for oo-
cyte development as mammalian oocytes are unable to
initiate glycolysis [5,17].
Many reports have identified the hormones and other fac-
tors in FF and their roles in evaluating oocyte quality. The
FF concentrations of hormones, prolactin, interleukin-1,
inhibin B, tumour necrosis factor, free fatty acids and dehy-
droepiandrosterone have been associated with the rates of
normal fertilisation and good embryo development and the
quality of the embryos [10,18,19]. However, their predictive
accuracy and sensitivity is very limited, and some reports
did not replicate these findings [20,21]. In contrast to all of
the factors mentioned above, BMP-15 is oocyte-derived,
indicating that it may be a more direct and valuable marker
than others for predicting oocyte quality. Unsurprisingly,
therefore, poor responders with a higher FF BMP-15 level
had better IVF outcomes, including a higher live birth rate.
Ageing is well-known to reduce the biological capacity
of a woman to reproduce. In this study, we found that
poor responders with both low FF BMP-15 and age >35
years had the worst IVF outcomes. Meanwhile, young
responders with high FF BMP-15 showed a betteroutcome. Even in the high BMP-15 group, increased ma-
ternal age was also associated with a significantly greater
miscarriage rate. These clinical consequences may be
due to the increase in the incidence of oocyte meiotic
errors with age [22]. Notably, the miscarriage rate of
women with high FF BMP-15 and aged less than or
equal to 35 years was just 5.3%.
Because IVF is an invasive and expensive treatment,
informing poor responders when to give up further IVF
cycles is important. The combination of BMP-15 and
age appears more accurate than any single marker in
predicting the clinical outcome, which may help poor
responders decide whether to continue with further
attempts. Moreover, for poor responders with one or
two mature follicles, proceeding to IVF may represent
their best chance for a successful pregnancy. Conversion
to intrauterine insemination or cancelling the current
cycle and making another attempt later does not im-
prove outcome [23]. Our and other studies suggest that
proceeding to IVF may still be the best choice for these
patients, especially for those younger than 35 years and
with a higher BMP-15 in FF. However, patients with
both low FF BMP-15 levels and aged >35 years should
be adequately warned of the possibility of the worst
pregnancy outcome. We did not determine the value of
FF BMP-15 in another IVF cycle in these patients, and
whether the BMP-15 level would be changed in the
following IVF cycle with adjusted stimulation protocols
remains unknown. Further studies using large samples
sizes should be undertaken before a clear conclusion
is made.
Conclusion
A high FF BMP-15 level combined with a young age
confers a better pregnancy opportunity. Therefore, fur-
ther IVF attempts should be encouraged for those poor
responders with high FF BMP-15 and young age. How-
ever, for older poor responders with low FF BMP-15, a
forewarning of a poor pregnancy outcome may help the
couple to change to other, more appropriate treatments
and avoid the cost and futility of repeated IVF cycles.
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